Abcam plc

NasdaqGS:ABCM Stock Report

Market Cap: US$5.5b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Abcam Valuation

Is ABCM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ABCM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$18.22
Fair Value
31.6% overvalued intrinsic discount
4
Number of Analysts

Below Fair Value: ABCM ($23.99) is trading above our estimate of fair value ($18.22)

Significantly Below Fair Value: ABCM is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ABCM?

Key metric: As ABCM is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ABCM. This is calculated by dividing ABCM's market cap by their current revenue.
What is ABCM's PS Ratio?
PS Ratio11.6x
SalesUK£379.70m
Market CapUK£4.40b

Price to Sales Ratio vs Peers

How does ABCM's PS Ratio compare to its peers?

The above table shows the PS ratio for ABCM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.2x
ALKS Alkermes
3.7x-0.07%US$5.8b
IONS Ionis Pharmaceuticals
6.1x22.4%US$4.9b
RARE Ultragenyx Pharmaceutical
7x29.6%US$3.9b
BPMC Blueprint Medicines
11.8x22.4%US$6.0b
ABCM Abcam
11.6x13.0%US$5.5b

Price-To-Sales vs Peers: ABCM is expensive based on its Price-To-Sales Ratio (11.6x) compared to the peer average (9.9x).

Price to Sales Ratio vs Industry

How does ABCM's PS Ratio compare vs other companies in the US Biotechs Industry?

134 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.1x-0.06%US$20.10b
INCY Incyte
3.2x4.0%US$13.63b
MRNA Moderna
3.9x19.3%US$12.70b
EXAS Exact Sciences
3.4x9.3%US$9.13b
ABCM 11.6xIndustry Avg. 11.0xNo. of Companies134PS01632486480+
134 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ABCM is expensive based on its Price-To-Sales Ratio (11.6x) compared to the US Biotechs industry average (10.9x).

Price to Sales Ratio vs Fair Ratio

What is ABCM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ABCM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio11.6x
Fair PS Ratio6x

Price-To-Sales vs Fair Ratio: ABCM is expensive based on its Price-To-Sales Ratio (11.6x) compared to the estimated Fair Price-To-Sales Ratio (6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ABCM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$23.66
0%
1.8%US$24.28US$23.28n/a4
Feb ’26n/a
US$23.66
0%
1.8%US$24.28US$23.28n/a4
Jan ’26n/a
US$23.66
0%
1.8%US$24.28US$23.28n/a4
Dec ’25n/a
US$23.66
0%
1.8%US$24.28US$23.28n/a4
Nov ’25n/a
US$23.66
0%
1.8%US$24.28US$23.28n/a4
Oct ’25n/a
US$23.66
0%
1.8%US$24.28US$23.28n/a4
Sep ’25n/a
US$23.66
0%
1.8%US$24.28US$23.28n/a4
Aug ’25n/a
US$23.66
0%
1.8%US$24.28US$23.28n/a4
Jul ’25n/a
US$23.66
0%
1.8%US$24.28US$23.28n/a4
Jun ’25n/a
US$23.66
0%
1.8%US$24.28US$23.28n/a4
May ’25n/a
US$23.66
0%
1.8%US$24.28US$23.28n/a4
Apr ’25n/a
US$23.66
0%
1.8%US$24.28US$23.28n/a4
Mar ’25n/a
US$23.66
0%
1.8%US$24.28US$23.28n/a4
Feb ’25n/a
US$23.66
0%
1.8%US$24.28US$23.28n/a4
Jan ’25n/a
US$23.66
0%
1.8%US$24.28US$23.28n/a4
Dec ’24US$23.97
US$23.66
-1.3%
1.8%US$24.28US$23.28n/a4
Nov ’24US$23.20
US$23.52
+1.4%
2.2%US$24.05US$23.02n/a4
Oct ’24US$22.63
US$23.64
+4.5%
3.6%US$25.10US$23.10n/a4
Sep ’24US$22.83
US$24.17
+5.9%
2.0%US$25.01US$23.83n/a4
Aug ’24US$23.17
US$26.91
+16.2%
27.9%US$40.02US$16.95n/a5
Jul ’24US$24.47
US$25.65
+4.8%
29.3%US$39.86US$17.70n/a5
Jun ’24US$16.25
US$19.94
+22.7%
13.9%US$24.61US$17.34n/a6
May ’24US$17.29
US$19.94
+15.3%
16.9%US$25.61US$15.77n/a6
Apr ’24US$13.46
US$18.96
+40.8%
17.6%US$24.89US$15.33n/a6
Mar ’24US$14.54
US$19.77
+36.0%
15.9%US$25.40US$15.31n/a6
Feb ’24US$14.58
US$20.63
+41.5%
18.3%US$25.68US$15.48n/a6
Analyst Price Target
Consensus Narrative from 4 Analysts
US$23.66
Fair Value
1.4% overvalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/07 12:12
End of Day Share Price 2023/12/05 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Abcam plc is covered by 26 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ian WilliamsAltium Capital Limited
Xian DengBerenberg
Michael RyskinBofA Global Research